Product sourcing reference

Tesamorelin / Ipamorelin Blend

A combination reference pairing tesamorelin with ipamorelin. Tesamorelin has an approved branded product; this blend does not.

Reference variants

Add Tesamorelin / Ipamorelin Blend to an order request

Quantities are individual vials (packs of 10). Orders need 100 vials and/or 20 spray bottles in total, mixed across items. Prices are reference estimates captured 2026-10-16; every request is pending eligibility and availability review. Per-unit figures are rounded to the cent from kit pricing, so a final quote may differ slightly.

9mg (6/3)Vial · confirm physical formCAS Multi-component

$40.25/vial$32.20/vial at 1,000+ vials of this item

Quantity of Tesamorelin / Ipamorelin Blend 9mg (6/3) in vials vials, packs of 10

Review your order request · Compare the full catalog

Confirm the exact substance

Tesamorelin is a stabilised GHRH analogue and ipamorelin is a selective ghrelin-receptor agonist. The blend ratio and salt forms should be specified on any request.

What the review will ask

Approval of a tesamorelin finished product does not extend to compounded or combined preparations. Review each component's pathway before requesting.

State the facility type, destination state and intended transaction. Do not send patient information.
Expect product- and lot-specific documentation to be requested before any material is accepted.
A listed price is a reference estimate. Availability, labeling, shipping and terms are confirmed in writing only after review.

Purchasing questions

Is this the same as the approved tesamorelin product?

No. The approved product contains tesamorelin alone in a specific formulation. A blend is a different preparation.

Separate the blend from tesamorelin alone

A two-component preparation is not the same product as a tesamorelin-only medicine. Ipamorelin acetate also appears in FDA's safety discussion, so a familiar first ingredient is not sufficient evidence.

Documentation to request

Obtain the ratio, component specifications and finished-formulation documentation. Review any supporting evidence for the combination actually proposed.

Regulatory context: FDA: substance-specific safety concerns. Source reviewed 2026-10-16. This source does not verify the identity, testing or availability of our catalog references.

Related guidance: Hormone clinic purchasing review. These references support a review, not a treatment recommendation or supply authorization.

Verify the current regulatory position

Use FDA human drug compounding guidance and applicable state requirements. This reference is not medical or legal advice and does not establish a lawful supply route.

Discuss sourcing requirements